Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
Add more filters










Database
Language
Publication year range
1.
Ther Apher Dial ; 2024 Jul 03.
Article in English | MEDLINE | ID: mdl-38960621

ABSTRACT

INTRODUCTION: Biological invasions may promote the onset of systemic inflammatory response syndrome in patients eligible for continuous renal replacement therapy (CRRT), leading to poor prognosis. Hence, we aimed to examine the inflammatory reactions in circulation using vitamin E-coated polysulfone hollow fiber membrane (ViLIFE). METHODS: Lipopolysaccharides were intravenously administered to pigs (2 µg/kg/30 min) to establish an acute inflammation model. Extracorporeal circulation was performed for 6 h in continuous venovenous hemodiafiltration mode using a hemofilter for CRRT filled with a polysulfone hollow fiber membrane or ViLIFE, and the differences in inflammatory reactions were evaluated. RESULTS: The ViLIFE group exhibited low platelet and cytokine levels (p < 0.05 vs. sham-CRRT group). Additionally, the ViLIFE group had lower lactate and high mobility group box 1 levels than the other groups. CONCLUSION: ViLIFE represents a promising CRRT modality that can inhibit the inflammatory response in circulation and inhibit further biological invasions.

2.
Sci Rep ; 12(1): 11533, 2022 07 07.
Article in English | MEDLINE | ID: mdl-35798783

ABSTRACT

The unfolded protein response (UPR) is an adaptive stress response pathway that is essential for cancer cell survival under endoplasmic reticulum stress such as during glucose starvation. In this study, we identified spautin-1, an autophagy inhibitor that suppresses ubiquitin-specific peptidase 10 (USP10) and USP13, as a novel UPR inhibitor under glucose starvation conditions. Spautin-1 prevented the induction of UPR-associated proteins, including glucose-regulated protein 78, activating transcription factor 4, and a splicing variant of x-box-binding protein-1, and showed preferential cytotoxicity in glucose-starved cancer cells. However, USP10 and USP13 silencing and treatment with other autophagy inhibitors failed to result in UPR inhibition and preferential cytotoxicity during glucose starvation. Using transcriptome and chemosensitivity-based COMPARE analyses, we identified a similarity between spautin-1 and mitochondrial complex I inhibitors and found that spautin-1 suppressed the activity of complex I extracted from isolated mitochondria. Our results indicated that spautin-1 may represent an attractive mitochondria-targeted seed compound that inhibits the UPR and cancer cell survival during glucose starvation.


Subject(s)
Glucose , Unfolded Protein Response , Benzylamines , Cell Survival , Endoplasmic Reticulum Stress , Glucose/metabolism , Quinazolines/pharmacology
3.
Ther Apher Dial ; 26(3): 507-514, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35247221

ABSTRACT

INTRODUCTION: Animal-model experimental systems capable of reflecting the effects of devices for continuous renal replacement therapy (CRRT) on living organisms are limited; thus, aimed to construct an animal model of AKI-CRRT using pigs. METHODS: Pigs were subjected to renal artery ischemia-reperfusion injury (IRI) and then to a maximum of 24 h of continuous hemodiafiltration (CHDF)-type CRRT. RESULTS: Post-IRI, pigs' creatinine levels rose threefold, and they exhibited 24 h of anuria and clear aggravation of oxidative stress, demonstrating successful induction of AKI for CRRT. Post-CRRT, no significant changes in their vital signs or hematological parameters were observed. Creatinine and blood urea nitrogen clearance, as well as suppression of increases in oxidative stress, were also confirmed. CONCLUSION: We believe that the use of our model can enable the preclinical evaluation of the effects of under-development CRRT devices on living organisms under conditions similar to those encountered in an actual clinical setting.


Subject(s)
Acute Kidney Injury , Continuous Renal Replacement Therapy , Hemodiafiltration , Acute Kidney Injury/therapy , Animals , Blood Urea Nitrogen , Creatinine , Female , Humans , Male , Renal Replacement Therapy , Swine
4.
J Dermatol ; 39(7): 625-31, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22211698

ABSTRACT

Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor which mediates a variety of functions in the skin including cutaneous inflammation. SLIGKV-NH(2) , an agonist peptide for PAR2, enhanced the interleukin (IL)-17-induced production of two CXC chemokines, CXCL1 (GRO-α) and CXCL8 (IL-8), in normal human epidermal keratinocytes (NHEK) in a concentration-dependent manner. The enhanced production of those chemokines was suppressed by a PAR2-specific siRNA. The SLIGKV-NH(2) -induced production of both CXCL1 and CXCL8 was markedly reduced by cyclosporine A. The enhanced production of CXCL1 was suppressed by 1α, 24R-dihydroxyvitamin D(3) , an active form of vitamin D(3) , and weakly by glucocorticoids, dexamethasone and clobetasol propionate, whereas production of CXCL8 was not altered by any of those receptor agonists. In psoriatic skin, the thickened upper spinous layer of the epidermis was positive for PAR2 protein and the expression of the IL17A mRNA was increased. These results suggest that the IL-17-induced pro-inflammatory reaction is enhanced by the activation of PAR2 in keratinocytes, and that the effect of PAR2 is differentially modulated by cyclosporine A, the active form of vitamin D(3) and glucocorticoids.


Subject(s)
Chemokine CXCL1/biosynthesis , Interleukin-17/metabolism , Interleukin-8/biosynthesis , Keratinocytes/immunology , Keratinocytes/metabolism , Receptor, PAR-2/metabolism , Cells, Cultured , Clobetasol/pharmacology , Cyclosporine/pharmacology , Dexamethasone/pharmacology , Dihydroxycholecalciferols/pharmacology , Glucocorticoids/pharmacology , Humans , Inflammation Mediators/metabolism , Interleukin-17/genetics , Interleukin-17/pharmacology , Keratinocytes/drug effects , Oligopeptides/pharmacology , Psoriasis/genetics , Psoriasis/immunology , Psoriasis/metabolism , RNA, Messenger/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/genetics , Receptor, PAR-2/agonists , Receptor, PAR-2/antagonists & inhibitors , Receptor, PAR-2/genetics
5.
Antimicrob Agents Chemother ; 53(5): 1760-5, 2009 May.
Article in English | MEDLINE | ID: mdl-19258275

ABSTRACT

In addition to their antibiotic effects, tetracyclines have anti-inflammatory action that is often beneficial in the control of inflammatory skin disorders. In this study, we examined the effects of tetracycline (TET) and two of its derivatives, doxycycline (DOX) and minocycline (MIN), on the production of interleukin-8 (IL-8) elicited by the activation of protease-activated receptor 2 (PAR2) in normal human epidermal keratinocytes (NHEK). In NHEK, the production of IL-8 stimulated by an agonist peptide of PAR2, SLIGKIV-NH(2), at 100 microM was significantly reduced by TET, DOX, or MIN at 5 and 10 microM, concentrations that are noncytotoxic. The tumor necrosis factor alpha (TNF-alpha)-induced production of IL-8 was synergistically augmented by SLIGKIV-NH(2), and that synergistic increase in the production of IL-8 was suppressed by 100 nM PAR2-specific small interfering RNA. It was also suppressed by TET, DOX, or MIN but not by the 14-membered-ring macrolide antibiotics erythromycin, roxithromycin, and clarithromycin, which also have anti-inflammatory activities, at 10 microM. These results suggest that tetracyclines attenuate the PAR2-IL-8 axis in keratinocytes and thereby effectively modulate proinflammatory responses in the skin.


Subject(s)
Anti-Bacterial Agents/pharmacology , Epidermis , Receptor, PAR-2/metabolism , Tetracyclines/pharmacology , Cells, Cultured , Epidermal Cells , Epidermis/drug effects , Epidermis/immunology , Humans , Inflammation , Interleukin-8/biosynthesis , Keratinocytes/drug effects , Keratinocytes/immunology , Receptor, PAR-2/drug effects
6.
Antimicrob Agents Chemother ; 52(4): 1538-41, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18212111

ABSTRACT

The production of interleukin-8 induced by the activation of protease-activated receptor 2 and its synergism with interleukin-1beta were modulated by 14-membered-ring macrolides, namely, roxithromycin, erythromycin, and clarithromycin, in cultured normal human epidermal keratinocytes. Those macrolides may attenuate the protease-activated receptor 2-interleukin-8 axis and thereby modulate proinflammatory responses in the skin.


Subject(s)
Interleukin-8/biosynthesis , Keratinocytes/drug effects , Macrolides/pharmacology , Receptor, PAR-2/drug effects , Receptor, PAR-2/metabolism , Cells, Cultured , Clarithromycin/chemistry , Clarithromycin/pharmacology , Epidermal Cells , Epidermis/drug effects , Erythromycin/chemistry , Erythromycin/pharmacology , Humans , Interleukin-1beta/metabolism , Keratinocytes/metabolism , Macrolides/chemistry , Roxithromycin/chemistry , Roxithromycin/pharmacology
7.
Chem Pharm Bull (Tokyo) ; 51(1): 53-7, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12520128

ABSTRACT

An easy and sensitive method for the quantitative determination of ofloxacin (OFLX), a new fluoroquinolone antimicrobial agent, in a pharmaceutical formulation, tablet, was developed by using solid-substrate room-temperature phosphorimetry (RTP) on a poly(vinyl alcohol) substrate. The method did not require a dry gas flush during the measurement of phosphorescence. The influence of different conditions such as solution pH and concentrations of heavy atoms, used as the enhancer, were studied. The phosphorescence intensity of OFLX was enhanced using NaOH and KI as enhancers. A linear relationship between concentration and RTP intensity for each standard solution was obtained in the concentration range of 4-18000 ng/ml, and the determination limit was 4 ng/ml. The proposed method was applied to a determination of OFLX in a commercial tablet, and the results were compared with those of fluorescence and UV methods. It was proven that OFLX in a commercial tablet can be accurately measured by this method with a very small amount of sample solution.


Subject(s)
Ofloxacin/analysis , Polyvinyl Alcohol/analysis , Technology, Pharmaceutical/methods , Temperature , Ofloxacin/chemistry , Polyvinyl Alcohol/chemistry , Spectrophotometry, Ultraviolet/methods , Substrate Specificity , Tablets
SELECTION OF CITATIONS
SEARCH DETAIL
...